ES

Eric Sullivan

Chimeric Therapeutics Limited | Non-Executive Director
Mr Sullivan is a senior finance and operations leader in private-to-public biotechnology company building, strategy, fundraising and financial planning. He brings with him an background in the biotechnology sector, having served in senior finance and operations leadership roles across a number of high-growth public biotech companies, including bluebird bio, Merrimack Pharmaceuticals and TCR2 Therapeutics. Additionally, his experience with blue-chip private companies, such as Oncorus, Gemini Therapeutics, and Triplet Therapeutics.

Company and Role

Company
Title
Tenure
Since
CHM
Chimeric Therapeutics Limited
  • Non-Executive Director
8mthAug 2023

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
CHM
Chimeric Therapeutics Limited
14/12/230N/A2,750,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
CHM
Chimeric Therapeutics Limited
14/12/23
Issued
2,750,000$0.027$74,250Issue of options